Novel drugs in the management of difficult-to-treat hepatitis C genotypes | Zendy

Lesley Miller | Zendy; Judith E. Cartwright | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Novel drugs in the management of difficult-to-treat hepatitis C genotypes

Author(s) -

Lesley Miller,

Judith E. Cartwright

Publication year - 2013

Publication title -

hepatic medicine evidence and research

Language(s) - English

Resource type - Journals

ISSN - 1179-1535

DOI - 10.2147/hmer.s48545

Subject(s) - ribavirin , medicine , pegylated interferon , hepatitis c virus , ns5a , adverse effect , hepatitis c , telaprevir , ns5b , sofosbuvir , combination therapy , immunology , virology , hepacivirus , virus

Hepatitis C virus (HCV) infection is the most common chronic bloodborne infection in the United States, with approximately 3.2 million Americans being chronically infected. Rates of HCV-related end-stage liver disease and its associated morbidity and mortality have yet to peak, so there is a pressing need for more effective and tolerable HCV treatment. HCV genotypes 1, 4, 5, and 6 are considered difficult to treat, and the need for improved therapies is especially great for persons infected with these genotypes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research